SI-BONE (NASDAQ:SIBN) Shares Up 3.9% - Should You Buy?

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report)'s share price traded up 3.9% during trading on Tuesday . The company traded as high as $14.40 and last traded at $14.24. 58,323 shares were traded during trading, a decline of 85% from the average session volume of 378,714 shares. The stock had previously closed at $13.71.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SIBN shares. Truist Financial raised their target price on SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price objective on shares of SI-BONE in a report on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $23.00.

SI-BONE Stock Performance

The stock has a market cap of $587.97 million, a price-to-earnings ratio of -15.24 and a beta of 1.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a fifty day moving average of $13.47 and a 200 day moving average of $14.10.

Insiders Place Their Bets

In other SI-BONE news, insider Anthony J. Recupero sold 3,305 shares of the business's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at $3,169,734.96. The trade was a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Laura Francis sold 10,048 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now owns 482,875 shares of the company's stock, valued at $6,074,567.50. This represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,679 shares of company stock valued at $276,439 in the last three months. 3.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On SI-BONE

Several large investors have recently modified their holdings of SIBN. FMR LLC lifted its holdings in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in SI-BONE during the second quarter worth $61,000. Walleye Capital LLC purchased a new position in shares of SI-BONE during the third quarter worth $144,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of SI-BONE by 24.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company's stock valued at $138,000 after buying an additional 2,108 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after buying an additional 903 shares during the period. Institutional investors and hedge funds own 98.11% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.